Commure Scribe vs Nabla: head-to-head (2026)

These are the two highest-scoring ambient scribes in our catalog after our 2026 hands-on testing — Nabla at 9.0 (our Editor's Pick) and Commure Scribe at 8.9. The gap is real but small, and the two tools win on different things.

If you're choosing between them, the decision isn't "which is better" — both are excellent. It's whether you weight compliance completeness, a real free tier and international reach (Nabla) or transparent self-serve pricing, bundled AI coding and a US-enterprise track record (Commure).

This is our 2026 head-to-head — sourced facts from each vendor's published material, plus our hands-on testing findings on both.

At a glance

	Commure Scribe	Nabla
Our editorial score	8.9 / 10	9.0 / 10 (Editor's Pick)
Status	Hands-on tested	Hands-on tested
HQ	Mountain View, USA	Brooklyn, USA / Paris, France
Founded	2017	2018
Compliance	HIPAA + SOC 2	HIPAA + SOC 2 Type II + GDPR + ISO 27001
Data residency	Onshore US; audio not stored after the visit	Not stored by default; EU presence
Free entry	7-day free trial (no permanent free tier)	Free tier — 30 consults/mo
Pro pricing	$89/mo web (or $708/yr); $129/mo iOS in-app	~US$120/mo (public pricing page offline as of May 2026)
AI coding	ICD-10 / CPT included at Pro	Coding part of the broader platform
Languages	60+ (depth trails the leaders)	35 (major markets, good depth)
Scale	20,000+ Scribe clinicians; HCA Healthcare exclusive ambient partner	85,000+ clinicians, 130+ health orgs, 20M+ encounters/yr
Valuation	$7B post-money (Sept 2025)	$120M raised through Series C (June 2025)

Note quality — our hands-on testing finding

This is the closest part of the comparison. In our hands-on testing, both tools sit at the top of the category for clinical-note quality. Commure scores 9.0 clinical precision / 8.8 note quality in our rubric; Nabla scores 9.0 / 8.9.

Commure is the strongest US-market note quality we've tested — multi-speaker handling and accented-English performance hold up where many incumbents drop or politely paraphrase. Nabla is its equal on precision and a hair ahead on note quality, with one nuance: Nabla polishes more aggressively — it rewrites the consultation into a fluent note, and on the densest visits that can occasionally smooth over a detail.

For a US-English, English-dominant practice the practical difference is small — both produce clean drafts with minimal editing. Run a week of real consultations on both and read the drafts line-by-line; on note quality alone you'd be happy with either.

Compliance and data residency

This is Nabla's clearest win. Nabla ships the full compliance quartet — HIPAA, SOC 2 Type II, GDPR and ISO 27001 — with no audio stored by default and a Paris office backing a first-class GDPR posture.

Commure ships HIPAA + SOC 2, with onshore US data residency, audio not stored after the visit, no third-party data sharing and a standard BAA. It's a solid posture for a US buyer — but GDPR is not publicly claimed and ISO 27001 isn't enumerated. Commure is built for the US market and doesn't pretend otherwise.

If you operate only in the US and US-onshore data is what you want, Commure's posture is fine. If you need GDPR, ISO 27001, or any cross-border footprint, Nabla is the clear fit. See our compliance quartet guide for the framework.

Pricing and the free-entry question

This is Commure's clearest win — on transparency.

Commure publishes its price: ScribePro is $89/month on the web (or $708/year, 30% off the regular $1,068). It's genuinely self-serve — you can sign up and run without a sales call. Two caveats: the pricing is fragmented — the Apple App Store in-app purchase is $129/month, higher than the web rate — and there's no permanent free tier, only a 7-day trial.

Nabla has a real free tier capped at 30 consultations per month — usable as a genuine multi-week evaluation or for a part-time clinician. But its Pro pricing is not transparent right now: the public pricing page is offline as of May 2026, with Pro reported around US$120/month — you'll need a sales conversation to confirm.

So: Commure wins if you want to see the price and self-serve onto it today. Nabla wins if you want to use the product free for longer than a week before deciding. Both let you test on real consultations first — see our AI scribe pricing guide.

Coding, languages and platform

AI coding: Commure includes AI-assisted ICD-10 / CPT coding at the Pro tier — not an add-on. Nabla treats coding as one capability within a broader platform that spans ambient capture, dictation, coding and agentic clinical workflows. If automated coding inside the scribe is a hard requirement, Commure bundles it cleanly at $89/mo.

Languages: Commure lists 60+ languages but, in our assessment, the depth trails Nabla, Heidi and Stenoly for non-English clinics. Nabla covers 35 languages with better per-language depth across the major markets. For an English-dominant US practice this is a non-issue; for a multilingual clinic Nabla is the safer pick. (Neither covers Norwegian or Swedish well — Nordic practices should look at Stenoly.)

Scale signals: Commure carries a $7B post-money valuation and is HCA Healthcare's exclusive ambient-scribing partner — a serious US-enterprise endorsement. Nabla runs at 85,000+ clinicians across 130+ health organizations and 20M+ annual encounters, with $120M raised through Series C. Both are well-capitalized for the long haul.

One Commure-specific note: the wider Commure platform absorbed Athelas and Augmedix, so the product surface is sprawling. If you only want the scribe layer, it stands on its own — but procurement should know what's in scope.

Who should choose which

Choose Commure Scribe if:

• You operate in the US and want transparent, self-serve pricing you can sign up to today.
• Bundled AI ICD-10 / CPT coding at the Pro tier matters to your workflow.
• US-onshore data residency is what you want (and you don't need GDPR).
• You value the HCA Healthcare-scale enterprise track record.

Choose Nabla if:

• Your procurement wants the complete HIPAA + SOC 2 Type II + GDPR + ISO 27001 quartet.
• You want a real free tier to evaluate over weeks, not a 7-day trial.
• You have any cross-border or EU footprint, or a multilingual patient base.
• You want a scribe on a clear agentic-platform roadmap beyond documentation.

Bottom line

Nabla is our Editor's Pick at 9.0 — and against Commure the margin is genuinely 0.1. Nabla edges it on compliance completeness, the real free tier and international readiness. Commure earns its 8.9 with the strongest US-market note quality we've tested, transparent self-serve pricing and bundled coding.

For a US-only buyer who wants to see the price, self-serve onboard and get coding in the box, Commure is an excellent — and arguably more practical — choice. For a buyer who needs the full compliance quartet, an EU footprint or a longer free evaluation, Nabla is the pick. You would not go wrong with either.

Track both tools' verified facts on their review pages: Commure Scribe and Nabla. For a side-by-side data view see /compare/commure-scribe-vs-nabla, or the full ranking.